Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 Cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation-Reference-Cited by-同舟云学术

Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 Cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation

Published:2008-12-15 Issue:12 Volume:113 Page:3323-3330
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Arakelyan Nina,Berthou Christian,Desablens Bernard,de Guibert Sophie,Delwail Vincent,Moles Marie-Pierre,Quittet Philippe,Jais Jean-Philippe,Colonna Pierre,Andrieu Jean-Marie,

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD;Canellos;N Engl J Med,1992

2. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial;Duggan;J Clin Oncol,2003

3. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi;Gobbi;J Clin Oncol,2005

4. Is there an effective salvage therapy for advanced Hodgkin's disease?;Canellos;Ann Oncol,1991

5. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure;Longo;J Clin Oncol,1992

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of mitoxantrone–melphalan and BEAM conditioning regimens in patients with lymphoma;Hematology/Oncology and Stem Cell Therapy;2021-04

2. Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review;Expert Review of Hematology;2020-08-02

3. PET positivity – the agony of choice: response assessment and interpretation of increased FDG uptake of residual mediastinal tissue after frontline therapy in Hodgkin lymphoma;Leukemia & Lymphoma;2020-01-16

4. Principles of Chemotherapy in Hodgkin Lymphoma;Hodgkin Lymphoma;2020

5. Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?;Leukemia & Lymphoma;2019-09-26